Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Colorcon
Chinese Patent Office
McKesson
Merck
AstraZeneca
Baxter
Johnson and Johnson
Medtronic
Cerilliant

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021018

« Back to Dashboard

NDA 021018 describes HUMALOG MIX 50/50 PEN, which is a drug marketed by Lilly and is included in one NDA. It is available from one supplier. Additional details are available on the HUMALOG MIX 50/50 PEN profile page.

The generic ingredient in HUMALOG MIX 50/50 PEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are thirty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.
Summary for 021018
Pharmacology for NDA: 021018
Ingredient-typeInsulin
Suppliers and Packaging for NDA: 021018
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HUMALOG MIX 50/50 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018 NDA Eli Lilly and Company 0002-7512 0002-7512-99 1 VIAL in 1 CARTON (0002-7512-99) > 10 mL in 1 VIAL
HUMALOG MIX 50/50 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018 NDA Eli Lilly and Company 0002-7512 0002-7512-01 1 VIAL in 1 CARTON (0002-7512-01) > 10 mL in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength50 UNITS/ML;50 UNITS/ML
Approval Date:Dec 22, 1999TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength50 UNITS/ML;50 UNITS/ML
Approval Date:Sep 6, 2007TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Aug 9, 2024Product Flag?YSubstance Flag?Delist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength50 UNITS/ML;50 UNITS/ML
Approval Date:Dec 22, 1999TE:RLD:No

Expired US Patents for NDA 021018

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly HUMALOG MIX 50/50 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-001 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Lilly HUMALOG MIX 50/50 KWIKPEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-002 Sep 6, 2007 ➤ Subscribe ➤ Subscribe
Lilly HUMALOG MIX 50/50 KWIKPEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-002 Sep 6, 2007 ➤ Subscribe ➤ Subscribe
Lilly HUMALOG MIX 50/50 KWIKPEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-002 Sep 6, 2007 ➤ Subscribe ➤ Subscribe
Lilly HUMALOG MIX 50/50 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-001 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Lilly HUMALOG MIX 50/50 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-001 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Lilly HUMALOG MIX 50/50 insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-001 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Lilly HUMALOG MIX 50/50 KWIKPEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-002 Sep 6, 2007 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Chinese Patent Office
Daiichi Sankyo
Express Scripts
Medtronic
Novartis
Citi
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot